4/A - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

4 - Oncology Institute, Inc. (0001799191) (Issuer)

CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or s

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 vs. prior yearFee-for-service growth of 9% in Q1 2025 over Q4 2024, highlighting the impact of our investments in referral relationship management and call center expansion.Strong start

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the Univ

CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley's 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and ot

CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI)("TOI"), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patients when enrolled in the TOI HVCC model. "Without compromising on the clinical outcomes for our oncology patients, TOI has again demonstrated the ability to drive down both Emergency Depar

CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t

CERRITOS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), a pioneer in value-based community oncology care, is proud to announce an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, a nationally recognized research site network. This initiative builds upon a successful collaboration in Florida and reflects TOI's ongoing commitment to integrating clinical research into community oncology settings. "Expanding our research collaboration with Helios Clinical is a natural next step," said Daniel Virnich, MD, CEO at TOI. "They've proven to be a highly capable partner, helping us streamline study a

CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents. The Florida Oncology Network includes TOI Clinics and a robust panel of value-focused medical and radiation oncologists strategically located throughout the state. The network is designed to provide comprehensive cancer care that is accessible, affordable, and focused on outcomes for patients and payor partners.

CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities purchase agreement (the "Securities Purchase Agreement") with accredited investors for a private placement that is expected to result in gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses (the "Private Placement"). The Private Placement includes participation from existing investors, as well as members of the Company's management team and Board of Directors and is expected to close on March

BTIG Research initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00

Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50

Guggenheim initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00

Jefferies initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $10.00

S-3 - Oncology Institute, Inc. (0001799191) (Filer)

144 - Oncology Institute, Inc. (0001799191) (Subject)

144 - Oncology Institute, Inc. (0001799191) (Subject)

144 - Oncology Institute, Inc. (0001799191) (Subject)

144 - Oncology Institute, Inc. (0001799191) (Subject)

8-K - Oncology Institute, Inc. (0001799191) (Filer)

EFFECT - Oncology Institute, Inc. (0001799191) (Filer)

8-K - Oncology Institute, Inc. (0001799191) (Filer)

10-Q - Oncology Institute, Inc. (0001799191) (Filer)

S-3 - Oncology Institute, Inc. (0001799191) (Filer)

SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or s

CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea

CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog

CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres

CERRITOS, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI), one of the largest value-based community oncology groups in the United States, today announced the appointment of Mark Pacala and Gabe Ling to serve on its Board of Directors ("Board"), effective immediately. "We are very pleased to have Mark and Gabe join our Board of Directors," said Brad Hively, Chief Executive Officer of TOI. "As TOI continues to expand and mature as a public company, we are excited to attract new talent to our board. Mark and Gabe bring significant industry experience and we look forward to benefitting from their insights and guidance as we continue to pursue our strateg

CERRITOS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ:TOI) today announced the appointment of Mihir Shah as chief financial officer, effective immediately. In this role, Mr. Shah will lead the Accounting, Finance, Revenue Cycle Management, and Investor Relations functions, playing a key role in driving TOI's public company success and executing the strategic growth plan. Mr. Shah succeeds Scott Dalgleish, who will serve as a senior advisor through a transition period. Mr. Shah joins TOI with fifteen years of industry leadership experience across public, private, and not-for-profit organizations. Most recently Mr. Shah served as chief fi

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 vs. prior yearFee-for-service growth of 9% in Q1 2025 over Q4 2024, highlighting the impact of our investments in referral relationship management and call center expansion.Strong start

CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t

CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

CERRITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2024 financial results after the market close on Tuesday, March 25, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the

CERRITOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and nine months ended September 30, 2024. Recent Operational Highlights Include 79.9% increase in Dispensary segment revenue compared to prior year quarterWelcomed Rob Carter, as our new Chief Financial Officer3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings to 13 our 2024 newly signed capitation contractsStarted second capitation contract in Florida directly with a health plan

CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call an

CERRITOS, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2024 and updated its full year 2024 guidance. Recent Operational Highlights Include 76% increase in Dispensary segment revenue compared to prior year quarter3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings our new 2024 newly signed capitation contracts to 10Exploring strategic alternatives to maximize shareholder value Second Quarter 2024 Financia

CERRITOS, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2024 financial results after the market close on Tuesday, August 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t

CERRITOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2024. Recent Operational Highlights Include: Successfully completed integration of first capitated risk contract direct to a health plan, and launched MSO model to enhance employed clinic locations, in the Florida market, effective January 1, 2024Partnered with MaxHealth to expand value-based care and assume clinical and financial responsibility to patients in five Florida counties7 new capitation and value-based contracts s

CERRITOS, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2024 financial results after the market close on Tuesday, May 14, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the